PhaseBio Pharmaceuticals Other Current Liabilities

PhaseBio Pharmaceuticals posts a other current liabilities of $12M as of June 2022. That compares with $5.9M in the prior-year period — up 110.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, PhaseBio Pharmaceuticals's other current liabilities was $5.9M. The latest reading is $12M — a 110.0% year-over-year increase (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

Other Current Liabilities is one piece of PhaseBio Pharmaceuticals's financial statement story. At $12M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PHAS's other current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; PhaseBio Pharmaceuticals's other metric pages and overview cover the third.

Judging PhaseBio Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current liabilities easier to interpret. Start with $12M here, then scan peer and history charts to see if the gap is persistent.